07 November 2019
Visiongain has launched a new pharma report “Spatial Genomics & Transcriptomics Market Report 2020-2030” Prospects by Spatial Transcriptomics (Sequencing-Based Methods, IHC, Microscopy-based RNA Imaging Techniques), Spatial Genomics (FISH, Microscopy-based Live DNA Imaging, Genome Perturbation Tools, Massively-Parallel Sequencing, Biochemical Techniques), Product (Consumables, Software, Instruments), End use (Translational Research, Academic Customers, Diagnostic Customers, Pharmaceutical Manufacturer) and Geography.
Global Spatial Genomics & Transcriptomics market is projected to grow on account of emerging potential of spatial genomic analysis as cancer diagnostic tool, technological advancements, and presence of emerging market players. The global market is projected to grow at a lucrative CAGR of 9% during the forecast period from 2020 to 2030 and is anticipated to surpass USD 200 Million by 2020.
Spacious genomics & transcriptomy helps researchers to see how cells are structured in relation to each other, not just what lies within a cell. Long beyond the reach of modern methods, the data offer invaluable insights related to disease's understanding. Spatial genomics & transcriptomics includes exploration and assortment of transcriptomics. It has different applications, especially in the field of molecular genetics. In the global spatial genomics & transcriptomics industry, there are many cases of fresh product launches over the forecast period.
Spatial genomics & transcriptomics is a relatively new discipline involving the determination of high-throughput data relating to the organizational structure of cell content from tissue and cell specimens. Conventional genomic approaches lack positional information on the quality of nucleic acid. In addition, rapid developments in the genomics field, ranging from tissue sequencing to single-cell sequencing, have gained greatly from techniques of spatial genomic sequencing. This is because single-cell sequencing makes it possible to classify complex tissues by determining the spatial origin of cells.
With increasing investment in spatial genomics & transcriptomics, as well as expanding supporting investor growth, it is projected to deliver the highest revenue attractiveness on the market. In terms of clearance of the political and legal framework, some countries have challenging entry barriers. Nevertheless, the market growth is expected to overcome the entry barriers with increasing awareness and adoption. It is anticipated that government funding and support and joint work with large pharmaceutical companies will be major drivers of this business in the near future. For example, 10X Genomics received a total funding of USD 243 million in January 2019, which will help company to expand its presence and develop products that provide invaluable insights for unlocking fundamental biology.
In contrast with spatial genomic methods, the significant applicability of spatial transcriptomic sequencing methods for the transcriptomic analysis of single cells has resulted in the greater revenue share of this process. This segment's dominance is also due to the adoption of automated sequencing workflows such as laser capture microdissection technique (LCM) to meet the increasing demand for single cell or biological samples nucleic acid sequencing. Realizing this market's importance in potential disease management, key players seek to focus on untapped, lucrative market avenues. The companies follow different business strategies to broaden their business presence.
North America dominated the global spatial genomics & transcriptomic market owing to the increasing adoption of spatial profiling solutions in cancer research coupled with increasing focus on genomics-based R&D. For example, in more than 70 research projects, the U.S.-based NanoString Technologies, Inc. GeoMx platform has been introduced, focusing on about 25 different types of cancer.
Asia Pacific is expected to register the highest CAGR due to rising public and private-sector investments. In 2018, for example, research on predicting gene regulatory networks from transcriptome datasets was jointly funded by the Japan Science and Technology Agency's Grant-in-Aid for Scientific Research, Advanced Low Carbon Technology Research and Development Program (ALCA), and CREST.
Some of the major players operating in this industry are 10x Genomics, Advanced Cell Diagnostics, CARTANA AB, Dovetail Genomics, Horizon Discovery Group plc, Illumina, Inc., NanoString Technologies, READCOOR, INC., S2 Genomics, Inc, and Seven Bridges Genomic, among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.